Uvax Bio’s Post

https://lnkd.in/dYiq2fHq Vaccines Beat CHIKV VACCINES. The European Medicine Agency is considering accelerated assessment review of PXVX0317, with potential for approval by both agencies in 2025. In this review, authors summarize published data from pre-clinical and clinical trials for the IXCHIQ and PXVX0317 vaccines.

Vaccine adjuvants: action and mechanisms ⚠️ ✳️ Adjuvants are defined as various components that enhance the immunogenicity of vaccines when administered in conjunction with vaccine antigens. 🅰️ Adjuvants enhance the immunogenicity of vaccines. a Vaccines without adjuvants induce modest production of T helper-polarizing cytokines, antibodies, and activated T cells. 🅱️ In contrast, vaccines with adjuvants promote the maturation of more APCs, increase the interaction between APCs and T cells, promote the production of greater numbers and more types of T helper-polarizing cytokines, multifunctional T cells, and antibodies, leading to broad and durable immunity, as well as dose and antigen savings. 💠 In the future post, we will continue discussing the mechanisms of adjuvants.

🏆 Stevie-winner Novavax is a biotechnology company dedicated to protecting global health through discovery, development, and commercialization of innovative vaccines. Since 1987, Novavax scientists have been refining the company’s protein-based platform, gaining valuable research experience on diseases like Ebola, Influenza, and RSV. Utilizing recombinant nanoparticle vaccine technology, they aim to revolutionize vaccine development by producing highly immunogenic and efficacious vaccines with an excellent safety profile. The company's pipeline includes candidates targeting a diverse array of infectious diseases, with several products progressing through clinical trials. In 2020, Novavax announced positive Phase 3 results for its influenza vaccine candidate. When the pandemic emerged, Novavax quickly shifted resources to develop a COVID-19 vaccine. In 2022, Novavax received authorization for its protein-based COVID-19 vaccine, offering a more traditional option, similar to well-known vaccines for flu, hepatitis, and shingles. The vaccine is approved in over 40 countries and has been granted WHO Emergency Use Listing. Novavax won a Silver #StevieAward for Pharmaceuticals Employer of the Year in the 2023 Stevie® Awards for Great Employers. Read the full blog ➡ https://hubs.ly/Q02zQy7m0

HIPRA (protein-based vaccine) or Pfizer (mRNA vaccine)?! 🔊 #Vaccines #COVID19 #HIPRA #Pfizer #MedicalResearch #Healthcare #OmicronVariant #PHH1V81 A detailed analysis compared HIPRA's protein-based vaccine, PHH-1V81, to Pfizer’s mRNA vaccine against the Omicron XBB.1.5 variant. Initial results indicate a stronger immune response from PHH-1V81.🧪 PHH-1V81, developed by HIPRA Scientific in Catalonia, is a recombinant protein-based vaccine designed to offer enhanced protection against Omicron variants. 💉 The Phase 2b/3 trial, with 905 participants randomized between PHH-1V81 and Pfizer’s BNT162b2, focused on neutralizing titers against Omicron XBB.1.16. Promisingly, PHH-1V81 demonstrated higher neutralizing titers and a superior safety profile with no serious adverse events reported. 🌍 Key points highlight PHH-1V81's stronger antibody response, excellent safety record, and its potential as an alternative to mRNA vaccines. The conclusion underscores PHH-1V81 as a hopeful option in the fight against SARS-CoV-2, particularly for vulnerable populations. 🏥 Despite these promising results, it’s essential to note the study's limitations, including interim findings with a 14-day follow-up, necessitating longer-term studies. 🕒 For those interested, the study is published in "Vaccines" and on ClinicalTrials_gov (NCT06181292), showcasing PHH-1V81's potential for effective and safe COVID-19 protection. 📑 https://lnkd.in/d--bJ_CQ TrialSite News

Moderna gets Blackstone backing for flu vaccine R&D An arm of the private equity firm has committed up to $750 million to support development Moderna’s mRNA-based vaccines for influenza. Dive Brief: - Blackstone Life Sciences will invest as much as $750 million on influenza vaccine research and development by Moderna, announcing Wednesday a private funding deal that gives the private equity firm rights to future payments and royalties. - Moderna has advanced an mRNA-based flu shot into late-stage testing and is also studying a combination flu and COVID-19 vaccine — part of a broad R&D strategy to follow the success of its standalone COVID shot. Later this year, the company intends to submit the flu shot for regulatory approval. - The funding agreement comes one day after Moderna revealed results for a “next-gen” COVID vaccine that it said showed higher immune responses than the biotechnology firm’s current product. This next-gen vaccine is being used in the combination flu and COVID vaccine that’s now in Phase 3 testing. https://lnkd.in/gWNaPtfS.

I am thrilled to share the publication of our latest research article: "A Non-Targeted Metabolomics Comparative Study on Plasma of Pfizer and Sinopharm COVID-19 Vaccinated Individuals, Assessed by (TIMS-QTOF) Mass Spectrometry." This study provides valuable insights into the metabolic differences in plasma between individuals vaccinated with Pfizer and Sinopharm COVID-19 vaccines. Utilizing cutting-edge TIMS-QTOF mass spectrometry, we have uncovered important findings contributing to our understanding of vaccine-induced metabolic changes. https://lnkd.in/dVtKN7it

Safety of Simultaneous vs Sequential #mRNA #COVID-19 and Inactivated #Influenza #Vaccines: A Randomized Clinical Trial « this randomized clinical trial assessing simultaneous vs sequential administration of mRNA COVID-19 and IIV4 vaccines, reactogenicity was comparable in both groups. These findings support the option of simultaneous administration of these vaccines » https://lnkd.in/daf---vK

Publication alert! https://lnkd.in/e9WpPhMw In this research article, we devised a vaccine adjuvant tailored for subunit vaccines. Subunit vaccines are renowned for their low toxicity, yet adjuvants are crucial for enhancing their immunogenicity. However, utilizing the same adjuvant can lead to adjuvant specific immune responses, which could be mitigated by offering alternative adjuvant options for subunit vaccines. In our study, we enhanced the suspendability of a metal-based adjuvant by incorporating Mannan, a polysaccharide. This modified adjuvant demonstrated robust humoral and cellular immune responses in the protein OVA mouse model.

Advances in #vaccine development and research in #Europe 💉 In a recent study by Vaccines Europe, it emphasized how important it is to continue #researching and developing #vaccines. Since #Covid19 it has become clear that, in a very short time, effective #medications can be created to prevent serious #diseases. 👉 https://lnkd.in/e-5942Pm Developments have been launched in Europe, including the vaccine development, #innovations and projects to address the current risks. Here are some of them: 🎗 Vaccines for #cancer related infections 💉 Speed up vaccine development 💊 #Antibiotic resistance: one of the great challenges 😷 Diseases that do not have a vaccine #health #qualitymedicines #publichealth #vaccinedevelopment #antibioticresistance #pharmaceuticalindustry #pharmaceuticalcompanies #pharma

https://lnkd.in/dBTv4_f8 Vaccines Beat VACCINE’S RESEARCH FUTURE As of 2023, the vaccine pipeline include almost 1,000 candidates, at different Research and Development phase, including innovative recombinant protein vaccines, nucleic acid vaccines and viral vector vaccines. Vaccines' technology platforms development varies by disease. Overall, vaccinology is progressing towards increasingly safe and effective products that are easily manufacturable and swiftly convertible. Real-life data analysis and operational research is needed to evaluate how such potential is exploited in public health practice to improve population health.